Real world data of efficacy and safety of erlotinib as first-line TKI treatment in EGFR mutation-positive advanced non-small cell lung cancer: Results from the EGFR-2013-CPHG study.
Fiche publication
Date publication
novembre 2020
Journal
Respiratory medicine and research
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DEBIEUVRE Didier
Tous les auteurs :
Payen T, Trédaniel J, Moreau L, Larivé S, Le Treut J, Nocent C, Hominal S, Grangeon V, Bizec JL, Molinier O, Debieuvre D
Lien Pubmed
Résumé
Phase III clinical trials have demonstrated the merits of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI) in the treatment of non-small cell lung cancer (NSCLC) patients with EGFR-activating mutations. Using a cohort of unselected patients treated with erlotinib, we sought to further describe patient and tumour characteristics, and to evaluate their progression-free survival (PFS) and overall survival (OS).
Mots clés
EGFR-TKI, Erlotinib, Non-small cell lung cancer, Overall survival, Progression-free survival
Référence
Respir Med Res. 2020 Nov 1;80:100795